These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 16777621)

  • 1. [The PI3K/Akt/mTOR pathway: a new therapeutic target in the treatment of acute myeloid leukemia].
    Dos Santos C; Récher C; Demur C; Payrastre B
    Bull Cancer; 2006 May; 93(5):445-7. PubMed ID: 16777621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia.
    Martelli AM; Evangelisti C; Chiarini F; Grimaldi C; Manzoli L; McCubrey JA
    Expert Opin Investig Drugs; 2009 Sep; 18(9):1333-49. PubMed ID: 19678801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [PI3K-AKT-mTOR pathway inhibitors].
    Cortot A; Armand JP; Soria JC
    Bull Cancer; 2006 Jan; 93(1):19-26. PubMed ID: 16455502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside.
    Martelli AM; Tazzari PL; Evangelisti C; Chiarini F; Blalock WL; Billi AM; Manzoli L; McCubrey JA; Cocco L
    Curr Med Chem; 2007; 14(19):2009-23. PubMed ID: 17691943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists.
    Carraway H; Hidalgo M
    Breast Cancer Res; 2004; 6(5):219-24. PubMed ID: 15318929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation.
    Follo MY; Mongiorgi S; Bosi C; Cappellini A; Finelli C; Chiarini F; Papa V; Libra M; Martinelli G; Cocco L; Martelli AM
    Cancer Res; 2007 May; 67(9):4287-94. PubMed ID: 17483341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted therapy of human osteosarcoma with 17AAG or rapamycin: characterization of induced apoptosis and inhibition of mTOR and Akt/MAPK/Wnt pathways.
    Gazitt Y; Kolaparthi V; Moncada K; Thomas C; Freeman J
    Int J Oncol; 2009 Feb; 34(2):551-61. PubMed ID: 19148492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises.
    Yap TA; Garrett MD; Walton MI; Raynaud F; de Bono JS; Workman P
    Curr Opin Pharmacol; 2008 Aug; 8(4):393-412. PubMed ID: 18721898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of the Akt/mTOR pathway on EGF-induced cell transformation.
    Nomura M; He Z; Koyama I; Ma WY; Miyamoto K; Dong Z
    Mol Carcinog; 2003 Sep; 38(1):25-32. PubMed ID: 12949840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth.
    Gibbons JJ; Abraham RT; Yu K
    Semin Oncol; 2009 Dec; 36 Suppl 3():S3-S17. PubMed ID: 19963098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK.
    Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
    Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):421-9. PubMed ID: 19661225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ATP-mediated protein kinase B Akt/mammalian target of rapamycin mTOR/p70 ribosomal S6 protein p70S6 kinase signaling pathway activation promotes improvement of locomotor function after spinal cord injury in rats.
    Hu LY; Sun ZG; Wen YM; Cheng GZ; Wang SL; Zhao HB; Zhang XR
    Neuroscience; 2010 Sep; 169(3):1046-62. PubMed ID: 20678995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML.
    Park S; Chapuis N; Bardet V; Tamburini J; Gallay N; Willems L; Knight ZA; Shokat KM; Azar N; Viguié F; Ifrah N; Dreyfus F; Mayeux P; Lacombe C; Bouscary D
    Leukemia; 2008 Sep; 22(9):1698-706. PubMed ID: 18548104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of LanthaScreen cellular assays for key components within the PI3K/AKT/mTOR pathway.
    Carlson CB; Robers MB; Vogel KW; Machleidt T
    J Biomol Screen; 2009 Feb; 14(2):121-32. PubMed ID: 19196698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy.
    Hidalgo M; Rowinsky EK
    Oncogene; 2000 Dec; 19(56):6680-6. PubMed ID: 11426655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The PI3K/Akt/mTOR pathway is activated in murine lupus nephritis and downregulated by rapamycin.
    Stylianou K; Petrakis I; Mavroeidi V; Stratakis S; Vardaki E; Perakis K; Stratigis S; Passam A; Papadogiorgaki E; Giannakakis K; Nakopoulou L; Daphnis E
    Nephrol Dial Transplant; 2011 Feb; 26(2):498-508. PubMed ID: 20709738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mammalian target of rapamycin promotes vincristine resistance through multiple mechanisms independent of maintained glycolytic rate.
    Vanderweele DJ; Rudin CM
    Mol Cancer Res; 2005 Nov; 3(11):635-44. PubMed ID: 16317089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Topics in mTOR pathway and its inhibitors].
    Dreyer C; Sablin MP; Faivre S; Raymond E
    Bull Cancer; 2009 Jan; 96(1):87-94. PubMed ID: 19211363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck.
    Amornphimoltham P; Patel V; Sodhi A; Nikitakis NG; Sauk JJ; Sausville EA; Molinolo AA; Gutkind JS
    Cancer Res; 2005 Nov; 65(21):9953-61. PubMed ID: 16267020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2-Arylthiazolidine-4-carboxylic acid amides (ATCAA) target dual pathways in cancer cells: 5'-AMP-activated protein kinase (AMPK)/mTOR and PI3K/Akt/mTOR pathways.
    Li CM; Narayanan R; Lu Y; Hurh E; Coss CC; Barrett CM; Miller DD; Dalton JT
    Int J Oncol; 2010 Oct; 37(4):1023-30. PubMed ID: 20811725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.